<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04188327</url>
  </required_header>
  <id_info>
    <org_study_id>33426/10/10</org_study_id>
    <nct_id>NCT04188327</nct_id>
  </id_info>
  <brief_title>Stellate Ganglion Block in Herpes Zoster</brief_title>
  <official_title>Utility of Early Serial Stellate Ganglion Block in Acute Herpes Zoster of Face and Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Mohamad Gamal Elmawy, M.D</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patient who will be presented to Tanta University Hospitals complaining of acute herpes&#xD;
      zoster with onset of vesicular eruption less than 7 days will be included in this clinical&#xD;
      study.&#xD;
&#xD;
      Patients will be excluded if they refused participation, had allergy to local anesthetics,&#xD;
      coagulopathy, local infection, glaucoma, or neurological deficit.&#xD;
&#xD;
      All the patients will receive acyclovir (antiviral therapy) and pregablin (analgesic) and the&#xD;
      patients will be classified into two groups:- Group I (control group): Patients will receive&#xD;
      sham block weekly for three times Group III (SGB group): Patients will receive stellate&#xD;
      ganglion block weekly for three times&#xD;
&#xD;
      The time of first block after the onset of vesicular eruption, the incidence of PHN, NPRS at&#xD;
      visit, duration of acute HZ , duration of PHN (if occurred), and the incidence of&#xD;
      complication will be measured.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This prospective randomized study will be carried out on adult patients complaining of acute&#xD;
      herpes zoster presented at Tanta University Hospitals after approval from ethics committee&#xD;
      for twelve months.&#xD;
&#xD;
      An informed consent will be taken from each patient. All data of patients will be&#xD;
      confidential with secret codes and private file for each patient. All given data will be used&#xD;
      for the current medical research only.&#xD;
&#xD;
      Any unexpected risk encountered during the course of the research will be cleared to the&#xD;
      participant as well as to the Ethical Committee on time. Every patient will receive an&#xD;
      explanation to the purpose of the study and will have a secret code number to ensure privacy&#xD;
      of the participants and confidentiality of their data.&#xD;
&#xD;
      The study will be terminated in case of incidence of severe hypotension no responding to&#xD;
      ephedrine (Mean arterial blood pressure less than 60 mmHg) or severe bradycardia not&#xD;
      responding to atropine (Heart rate less than 40 b/min). The participants and the ethical&#xD;
      committee will be announced.&#xD;
&#xD;
      There will be adequate supervision to maintain the privacy of patients and confidentiality of&#xD;
      data. There will be no conflict of interest, nor conflict with religion, law, or society&#xD;
      standards. The research will be beneficial to the society and has no risk of environmental&#xD;
      pollution.&#xD;
&#xD;
      After inclusion, adequate history taking, clinical examination, and laboratory investigation&#xD;
      (as needed) will be done for all patients. Every patient will be educated about the use of&#xD;
      the 0-10 numerical rating scale for pain assessment (NPRS: with endpoints of 'no pain' and&#xD;
      'worst pain').&#xD;
&#xD;
      Each patient will receive:&#xD;
&#xD;
        -  Acyclovir 800 mg orally every 5 times per day (for immuno-compromised patients 10 mg/kg&#xD;
           IV 3 times per day) for 7 days.&#xD;
&#xD;
        -  Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every&#xD;
           12 hours&#xD;
&#xD;
      Groups:&#xD;
&#xD;
      Participants will be divided into two groups; each group consists of (88) patients. The&#xD;
      sample size calculation was made using Epi-Info software program created by the WHO&#xD;
&#xD;
        -  Group I (control group): Patients will receive sham block weekly for three times&#xD;
&#xD;
        -  Group II (SGB group): Patients will receive stellate ganglion block weekly for three&#xD;
           times&#xD;
&#xD;
      Equipment&#xD;
&#xD;
        -  10-mL syringe - For local anesthetic&#xD;
&#xD;
        -  22- or 25-gauge, 1.5-inch short-bevel needle&#xD;
&#xD;
        -  Skin temperature monitor&#xD;
&#xD;
        -  Ultrasound machine with a 6-12 MHz linear type probe.&#xD;
&#xD;
        -  Appropriate equipment and medications for medical resuscitation&#xD;
&#xD;
      Technique of SGB:&#xD;
&#xD;
      The patient will be positioned supine with slight neck extension and rotation to the&#xD;
      contralateral side. After adequate asepsis of the neck, the probe will be placed&#xD;
      perpendicular to tracheal axis at the cricoid cartilage. An initial scan will be obtained to&#xD;
      identify structures: thyroid gland, carotid artery and jugular vein.&#xD;
&#xD;
      The transverse process at C6 should be identified as the initial landmark because of its&#xD;
      prominent anterior tubercle (The Chassaignac tubercle). The long muscle of the neck (longus&#xD;
      colli) is found above it.&#xD;
&#xD;
      The puncture should be in-plane to see the tip of the needle all the time. The needle will be&#xD;
      directed medially until it passes through the deep cervical fascia above the longus colli&#xD;
      muscle.&#xD;
&#xD;
      Considering repeated aspiration test, a 7 ml injectate (for SGB group: 6ml bupivicain 0.25%+&#xD;
      1 ml methylpredinosolone 40mg) will be done while observing the dissection between the&#xD;
      carotid artery and the longus colli muscle.&#xD;
&#xD;
      After finishing the block:&#xD;
&#xD;
      The patient will be transferred to the recovery room for 30-60 min to assess any potential&#xD;
      complications. After that he will be discharged.&#xD;
&#xD;
      Review appointments will be arranged weekly for 4 weeks then every 2 weeks for 4 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">November 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 14, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective randomized controlled study</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>The patients will be blind through the use of closed sealed envelops.&#xD;
The investigator will be blind through the use of sham block in the control group.&#xD;
The measurement will be collected by anesthesiologist not participating in the study and blinded to its group</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Post-herpetic neuralgia</measure>
    <time_frame>within 3 months of the last stellate ganglion block</time_frame>
    <description>The incidence of chronic neuropathic pain in the face or the neck after herpes zoster</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The duration of herpes zoster</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>The time from diagnosis of HZ till resolving of it</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Pain</condition>
  <condition>Neuropathic</condition>
  <arm_group>
    <arm_group_label>Control group(Group I)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients will receive sham stellate ganglion block weekly for three times</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stellate Ganglion block group (Group II)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive stellate ganglion block weekly for three times with injection of 6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stellate ganglion block</intervention_name>
    <description>While the patient is in a supine position with slight neck extension and rotation to the contralateral side, in-plane ultrasound guided stellate ganglion block will be performed with injection of 7 ml injectate (6ml bupivicain 0.25%+ 1 ml methylpredinosolone 40mg).&#xD;
Each patient will receive:&#xD;
Acyclovir 800 mg orally every 5 times per day 7 days.&#xD;
Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours</description>
    <arm_group_label>Stellate Ganglion block group (Group II)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sham Stellate ganglion block</intervention_name>
    <description>The patient will be positioned supine with slight neck extension and rotation to the contralateral side. Under US guidance, a sham stellate ganglion block will be performed with injection of a 1ml injectate of normal saline will be done while observing the dissection between the carotid artery and the longus colli muscle.&#xD;
Each patient will receive:&#xD;
Acyclovir 800 mg orally every 5 times per day for 7 days.&#xD;
Pregabalin start with 50 mg orally every 8hours for 7 days then increase to 150 mg every 12 hours</description>
    <arm_group_label>Control group(Group I)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who is presented to the pain clinic, diagnosed with acute herpes zoster of&#xD;
             the face and/ or neck with onset of vesicular eruption less than seven days&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient refusal or un-cooperation&#xD;
&#xD;
          -  Known history of allergy to local anesthetics&#xD;
&#xD;
          -  Local infection at the site of the block&#xD;
&#xD;
          -  Platelet count less than 75,000/ cc&#xD;
&#xD;
          -  Neurological deficit in the upper limb&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Bradycardia&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sameh Ismaiel, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of Anesthesia and Intensive Care, Tanta University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sohair Soliman, Professor</last_name>
    <phone>00201283929049</phone>
    <email>sohairsoliman@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mohamed Aly, M.D</last_name>
    <phone>00201099957971</phone>
    <email>moh_aly_2005@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Tanta</city>
        <state>Algharbia</state>
        <zip>31511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sameh Ismaiel, M.D</last_name>
      <phone>00201002977048</phone>
      <email>samehabdelkhalik1982@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Abduallah, M.D</last_name>
      <phone>00201099957971</phone>
      <email>moh_aly_2005@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Fayoum</city>
        <zip>63512</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamed Awad, M.D</last_name>
      <phone>00201223881100</phone>
    </contact>
    <contact_backup>
      <last_name>Mohamed Fouad, M.D</last_name>
      <phone>00201111645345</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Tanta University hospitals</name>
      <address>
        <city>Tanta</city>
        <zip>31511</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sohair Soliman, Professor</last_name>
      <phone>00201283929049</phone>
      <email>sohairsoliman@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mohamed Abduallah, M.D</last_name>
      <phone>00201099957971</phone>
      <email>moh_aly_2005@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 28, 2019</study_first_submitted>
  <study_first_submitted_qc>December 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 5, 2019</study_first_posted>
  <last_update_submitted>July 24, 2021</last_update_submitted>
  <last_update_submitted_qc>July 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Sameh Abdelkhalik Ahmed Ismaiel</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Herpes Zoster</keyword>
  <keyword>Stellate ganglion</keyword>
  <keyword>Post-herpetic neuralgia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Once the study had been successfully completed, the data will be shared for other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

